AbbVie Inc (ABBV)vsNyxoah (NYXH)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
NYXH
Nyxoah
$2.88
+0.35%
HEALTHCARE · Cap: $64.81M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 409732% more annual revenue ($62.82B vs $15.33M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
NYXH
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for NYXH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 498.9% year-over-year
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : NYXH
The strongest argument for NYXH centers on Revenue Growth, Price/Book. Revenue growth of 498.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : NYXH
The primary concerns for NYXH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while NYXH is a hypergrowth play — different risk/reward profiles.
NYXH carries more volatility with a beta of 0.89 — expect wider price swings.
NYXH is growing revenue faster at 498.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Nyxoah
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nyxoah is an innovative medical technology company at the forefront of addressing obstructive sleep apnea (OSA) through its unique Genio system, which leverages minimally invasive hypoglossal nerve stimulation techniques. With a steadfast commitment to clinical validation, extensive research, and robust partnerships, Nyxoah is poised to enhance patient outcomes and improve the quality of life for millions affected by OSA. The company’s strategic focus on innovation within the sleep medicine sector positions it advantageously to meet the growing demand for effective treatment solutions, indicating strong potential for sustainable growth within the healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?